RA CAPITAL MANAGEMENT, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001346824

What is a 13F filing? Who files one and when · What 13F filings can't tell you

LargeFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 84 positions · Total reported value $11.51B · Top-10 concentration 60.4% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.4% · 15 new · 12 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.6% · vs SPY -15.8% · Prev Value $11.51B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -1.6% · vs SPY -3.7% · Latest Value $9.72B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, RA CAPITAL MANAGEMENT, L.P. disclosed 84 equity positions with a combined reported value of $11.51B. The filing implies a focused portfolio: its ten largest positions account for 60.4% of reported value. HoldingsHub classifies the profile as Large / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were ASND ($2.74B), PBLS ($791.91M), RYTM ($740.22M). By sector, the heaviest allocations are Health Care 98.1%, Financials 0.2%. Versus the prior quarter, allocation shifted toward Health Care (+1.4pp) and away from Other (-1.3pp).

Versus the prior quarter, RA CAPITAL MANAGEMENT, L.P. opened 15 new positions, trimmed 12 and fully exited 11, a turnover rate of 38.4% of positions. The portfolio's overlap with the prior quarter was 67% of names.

The largest new positions opened in Q2 2026 were PBLS ($791.91M), COAG ($286.81M), ABVX ($150.92M).

Of the 11 positions fully exited versus the prior quarter, the largest were DNTH ($219.18M), PRAX ($120.43M), SRPT ($84.92M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • PBLS PARABILIS MEDICINES INC · $791.91M
  • COAG HEMAB THERAPEUTICS HLDGS INC · $286.81M
  • ABVX ABIVAX SA · $150.92M
  • ORKA ORUKA THERAPEUTICS INC · $147.95M
  • NTLA INTELLIA THERAPEUTICS INC · $76.60M
  • DFTX DEFINIUM THERAPEUTICS INC · $70.56M
  • SANA SANA BIOTECHNOLOGY INC · $65.44M
  • PRLD PRELUDE THERAPEUTICS INC · $34.52M

Fully Exited (vs previous quarter)

  • DNTH DIANTHUS THERAPEUTICS INC · prev qtr: $219.18M
  • PRAX PRAXIS PRECISION MEDICINES I · prev qtr: $120.43M
  • SRPT SAREPTA THERAPEUTICS INC · prev qtr: $84.92M
  • SYRE SPYRE THERAPEUTICS INC · prev qtr: $81.79M · history
  • FULC FULCRUM THERAPEUTICS INC · prev qtr: $46.43M
  • OLMA OLEMA PHARMACEUTICALS INC · prev qtr: $38.77M
  • DSGN DESIGN THERAPEUTICS INC · prev qtr: $31.63M
  • TVTX TRAVERE THERAPEUTICS INC · prev qtr: $22.19M

Insider Transactions (Form 4)

Latest RA CAPITAL MANAGEMENT, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 164,891 $16.00 SEC filing
2026-11-02 Buy Bambusa Therapeutics, Inc. 2,335,109 $16.00 SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 1,331,080 — SEC filing
2026-11-02 Conversion Bambusa Therapeutics, Inc. 3,144,858 — SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 263,911 $14.92 SEC filing
2026-10-30 Buy Bambusa Therapeutics, Inc. 189,909 $14.23 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 107,170 $3.36 SEC filing
2026-10-29 Sell LENZ Therapeutics, Inc. 451,998 $3.36 SEC filing

All insider transactions →

Fund Profile

RA Capital Management is a Boston-based investment firm founded by Peter Kiernan, specializing in healthcare-focused investments with a long-term, value-oriented approach.

Investment Approach

Focuses on healthcare sector investments

Long-term, value-oriented strategy

Deep fundamental research and analysis

Asset Classes & Strategy

Primarily invests in public equities

Also manages private investments in healthcare companies

Concentrated portfolio approach with significant positions in healthcare companies

Key Personnel

Peter Kiernan: Founder and portfolio manager

Team of experienced investment professionals with healthcare expertise

Notable Facts

Founded in 2002

Manages approximately $16.4 billion in assets

Files SEC Form 13F for US equity positions

This profile is based on publicly available information and should not be considered as official disclosure from the firm.

AI Rebalance Analysis

1. Overall Direction and Market View: The RA Capital Management, L.P. fund's Q2 2026 rebalancing appears to be cautiously optimistic, with a focus on health care sector investments, particularly in biotechnology and pharmaceuticals. This indicates a belief in the potential growth within these sectors. 2. Key Moves: - Added: Parablis Medicines (PBLS) and Hemab Therapeutics Holdings (COAG), signaling a willingness to explore new opportunities. - Reduced: Edgewise Therapeutics (EWTX) by 19.5%, suggesting a reevaluation of the company's prospects or a shift in strategy. - No Change: Most of the other positions were held steady, with a minor share increase in some, indicating a conservative stance. 3. Portfolio Structure: - Passive/Active: The fund seems to lean towards a passive approach with a focus on holding positions steady unless a compelling reason for change arises. - Sector Bias: Strong bias towards the Health Care sector, specifically biotechnology and pharmaceuticals. - Risk Appetite: The portfolio maintains a moderate risk appetite, with no major shifts in risk profile. 4. Per-Holding One-Liner: - ASND (Ascendis Pharma A/S): A biopharmaceutical company focused on developing therapies for rare and orphan diseases. - PBLS (Parablis Medicines Inc. COM): A biotechnology company focused on developing novel treatments for neurological disorders. - RYTM (Rhythm Pharmaceuticals Inc.): A biopharmaceutical company developing therapies for rare metabolic diseases. - PCVX (Vaxcyte Inc.): A biotechnology company focused on developing live attenuated vaccines. - SION (Sionna Therapeutics Inc. COM): A biopharmaceutical company focusing on the development of treatments for neurodegenerative diseases. - TYRA (Tyra Biosciences Incorporated): A biotechnology company focused on the development of novel therapies for inflammatory and metabolic diseases. - EWTX (Edgewise Therapeutics Inc. COM): A biopharmaceutical company working on therapies for oncology and rare genetic diseases. - NAMS (NewAmsterdam Pharma Company): A biopharmaceutical company developing treatments for infectious diseases. - COAG (Hemab Therapeutics Holdings): A biopharmaceutical company focusing on the development of treatments for hemophilia and other bleeding disorders. - SEPN (Septerna Inc.): A biopharmaceutical company focused on the development of therapies for orphan genetic diseases. 5. One-Sentence Style Summary: RA Capital Management's Q2 2026 rebalancing reflects a conservative, sector-focused strategy in the health care space, with a particular interest in biotechnology and pharmaceuticals.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 98.1%
Financials 0.2%
Technology 0.1%
Materials 0.1%
Other 1.6%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 10.28M $2.74B 23.83%
23.83%
Hold
2 28.93M $791.91M 6.88%
6.88%
New
3 6.67M $740.22M 6.43%
6.43%
Hold
4 11.47M $667.02M 5.80%
5.80%
Hold
5 9.91M $435.72M 3.79%
3.79%
Hold
6 12.20M $389.62M 3.39%
3.39%
Hold
7 8.39M $341.00M 2.96%
2.96%
Reduce
8 9.55M $323.66M 2.81%
2.81%
Hold
9 7.81M $286.81M 2.49%
2.49%
New
10 7.00M $234.29M 2.04%
2.04%
Hold
11 7.26M $215.43M 1.87%
1.87%
Hold
12 7.69M $207.55M 1.80%
1.80%
Hold
13 7.64M $205.28M 1.78%
1.78%
Reduce
14 2.45M $179.21M 1.56%
1.56%
Hold
15 8.02M $178.55M 1.55%
1.55%
Hold
16 17.96M $174.17M 1.51%
1.51%
Add
17 11.19M $171.87M 1.49%
1.49%
Hold
18 23.56M $160.41M 1.39%
1.39%
Hold
19 15.83M $158.27M 1.38%
1.38%
Hold
20 26.98M $156.73M 1.36%
Form 4 · 1 →
1.36%
Hold
21 1.25M $153.94M 1.34%
1.34%
Reduce
22 1.13M $150.92M 1.31%
1.31%
New
23 1.55M $147.95M 1.29%
1.29%
New
24 11.30M $147.36M 1.28%
Form 4 · 4 →
1.28%
Hold
25 12.04M $120.24M 1.04%
1.04%
Add
26 5.74M $109.13M 0.95%
0.95%
Add
27 10.86M $87.00M 0.76%
0.76%
Hold
28 5.27M $84.92M 0.74%
0.74%
Add
29 3.67M $81.57M 0.71%
0.71%
Hold
30 4.53M $76.60M 0.67%
0.67%
New
31 2.21M $71.68M 0.62%
0.62%
Hold
32 1.50M $70.56M 0.61%
0.61%
New
33 12.72M $67.30M 0.58%
0.58%
Add
34 5.05M $67.16M 0.58%
0.58%
Hold
35 18.75M $65.44M 0.57%
0.57%
New
36 2.40M $62.42M 0.54%
0.54%
Hold
37 667.21K $61.78M 0.54%
0.54%
Hold
38 20.99M $56.05M 0.49%
0.49%
Hold
39 42.81M $54.80M 0.48%
0.48%
Reduce
40 9.45M $49.11M 0.43%
0.43%
Add
41 3.49M $46.44M 0.40%
0.40%
Hold
42 2.40M $44.22M 0.38%
Form 4 · 1 →
0.38%
Reduce
43 17.75M $43.50M 0.38%
0.38%
Hold
44 1.31M $42.36M 0.37%
0.37%
Reduce
45 1.67M $40.97M 0.36%
0.36%
Add
46 8.00M $37.36M 0.33%
0.33%
Hold
47 318.55K $37.29M 0.32%
0.32%
Hold
48 1.51M $36.31M 0.32%
0.32%
Hold
49 20.06M $36.12M 0.31%
0.31%
Hold
50 6.48M $34.52M 0.30%
0.30%
New

FAQ

What did RA CAPITAL MANAGEMENT, L.P. buy in 2026-Q2?

In its 2026-Q2 13F filing, RA CAPITAL MANAGEMENT, L.P. reported 84 equity positions worth $11.51B in aggregate; its largest disclosed positions were ASND ($2.74B), PBLS ($791.91M), RYTM ($740.22M).

How large is RA CAPITAL MANAGEMENT, L.P.'s portfolio?

RA CAPITAL MANAGEMENT, L.P. reported $11.51B of long equity holdings across 84 positions as of 2026-Q2. Top-10 holdings account for 60.4% of reported value.

What is RA CAPITAL MANAGEMENT, L.P.'s investment style?

HoldingsHub classifies the portfolio as Large / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/ra-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →